FindTrial
Sign In

Prediction of curative effect and mechanism of neoadjuvant immunotherapy for non-small cell lung cancer based on respiratory microbial metagenomics

Prediction of curative effect and mechanism of neoadjuvant immunotherapy for non-small cell lung cancer based on respiratory microbial metagenomics

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037309
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Gold Standard:Clinical outcome
Index test:Prediction&#32
model&#32
of&#32
curative&#32
effect&#32
neoadjuvant&#32
immunotherapy&#32
for&#32
non-small&#32
cell&#32
lung&#32
cancer&#32
based&#32
on&#32
respiratory&#32
microbial&#32
metagenomics.

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients receiving neoadjuvant immunotherapy.

Exclusion criteria

Exclusion criteria: No serious systemic diseases such as severe liver and kidney diseases, malignant tumors, etc. in the past.

Design outcomes

Primary

MeasureTime frame
Microbiological profiles based on metagenome of respiratory tract microorganisms;SEN, SPE, ACC, AUC of ROC, PPV, NPV;—

Countries

China

Contacts

Public ContactLong Jiang

Shanghai Chest Hospital

dylan919@139.com+86 13651656310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026